LMR Partners LLP Acquires 15,288 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

LMR Partners LLP raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 96.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,177 shares of the biopharmaceutical company's stock after purchasing an additional 15,288 shares during the period. LMR Partners LLP's holdings in Intra-Cellular Therapies were worth $2,281,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Oak Ridge Investments LLC bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at approximately $811,000. SG Americas Securities LLC raised its holdings in Intra-Cellular Therapies by 962.7% in the 2nd quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company's stock worth $3,341,000 after purchasing an additional 44,188 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Intra-Cellular Therapies by 12.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company's stock valued at $120,723,000 after purchasing an additional 191,416 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Intra-Cellular Therapies by 232.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company's stock valued at $3,519,000 after purchasing an additional 35,528 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its stake in Intra-Cellular Therapies by 6.5% in the third quarter. TimesSquare Capital Management LLC now owns 438,083 shares of the biopharmaceutical company's stock worth $32,055,000 after buying an additional 26,600 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company's stock.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Sharon Mates sold 53,013 shares of the firm's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. This trade represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 179,471 shares of company stock worth $13,670,383. Company insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI traded up $0.88 during mid-day trading on Tuesday, reaching $83.35. The stock had a trading volume of 698,665 shares, compared to its average volume of 862,086. The stock has a market cap of $8.84 billion, a PE ratio of -95.75 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 1 year low of $56.83 and a 1 year high of $93.45. The company has a fifty day moving average price of $78.43 and a 200 day moving average price of $74.40.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same period in the previous year, the company earned ($0.25) earnings per share. The company's revenue for the quarter was up 39.0% compared to the same quarter last year. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on ITCI shares. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Piper Sandler raised Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. The Goldman Sachs Group lowered their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Royal Bank of Canada upped their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an "outperform" rating in a research report on Friday, October 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.